/DMTTF
DMTTF Stock - Small Pharma Inc.
Healthcare|BiotechnologyOTC
$0.11-9.69%
$0.01 (-9.69%) • Oct 20
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.86
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.12
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DMTTF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.11 – $0.11
TARGET (TP)$0.13
STOP LOSS$0.10
RISK/REWARD1:1.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.85
52W High$0.19
52W Low$0.04
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Revenue | N/A | N/A | $77,643 |
| Gross Profit | N/A | N/A | $77,643 |
| Gross Margin | N/A | N/A | 100.0% |
| Operating Income | $-24,680,068 | $-17,952,253 | $-5,621,026 |
| Net Income | $-22,836,213 | $-22,265,684 | $-7,035,300 |
| Net Margin | N/A | N/A | -9061.1% |
| EPS | $-0.07 | $-0.07 | $-0.02 |
Company Overview
Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. Its clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. The company's product includes SPL026 Placebo, which is in clinical Phase IIA for the treatment of major depressive disorder. Its preclinical stage programs include SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801 oral formulation of 6-hydroxynorketamin. The company was incorporated in 2015 and is headquartered in London, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
DMTTFBeat Rate
0%
Last 6 quarters
Avg Surprise
-18.8%
EPS vs Estimate
Beats / Misses
0/4
2 met exactly
Latest EPS
$-0.01
Q2 2023
EPS Surprise History
Q3 22
No data
Q4 22
-13.1%
$-0.02vs$-0.02
Q4 22
No data
Q1 23
0.0%
$-0.02vs$-0.02
Q1 23
No data
Q1 23
No data
Q2 23
No data
Q2 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | May 31, 2023 | — | $-0.01 | — | — |
Q2 2023 | May 31, 2023 | — | $-0.01 | — | — |
Q1 2023 | Feb 28, 2023 | — | $-0.01 | — | — |
Q1 2023 | Feb 28, 2023 | — | $-0.01 | — | — |
Q1 2023 | Jan 25, 2023 | $-0.02 | $-0.02 | 0.0% | = MET |
Q4 2022 | Nov 30, 2022 | — | $-0.02 | — | — |
Q4 2022 | Oct 14, 2022 | $-0.02 | $-0.02 | -13.1% | ✗ MISS |
Q3 2022 | Aug 31, 2022 | — | $-0.02 | — | — |
Q3 2022 | Jul 15, 2022 | $-0.01 | $-0.02 | -33.3% | ✗ MISS |
Q1 2022 | Jan 31, 2022 | $-0.01 | $-0.02 | -33.3% | ✗ MISS |
Q4 2021 | Nov 1, 2021 | $-0.01 | $-0.01 | 0.0% | = MET |
Q3 2021 | Jul 30, 2021 | $-0.01 | $-0.02 | -33.3% | ✗ MISS |
Q2 2021 | Apr 29, 2021 | — | $-0.02 | — | — |
Q1 2021 | Feb 28, 2021 | — | $-0.01 | — | — |
Q4 2020 | Nov 30, 2020 | — | $-0.00 | — | — |
Q3 2020 | Aug 31, 2020 | — | $-0.00 | — | — |
Q2 2020 | May 31, 2020 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about DMTTF
What is DMTTF's current stock price?
Small Pharma Inc. (DMTTF) is currently trading at $0.11 per share. The stock has moved -9.69% today.
What is the analyst price target for DMTTF?
No analyst price targets are currently available for this stock.
What sector is Small Pharma Inc. in?
Small Pharma Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is DMTTF's market cap?
Small Pharma Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does DMTTF pay dividends?
No, Small Pharma Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACOGF
Alpha Cognition Inc.
$5.72
Mkt Cap: $0.0B
CSWYY
China Shineway Pharmaceutical Group Limited
$19.25
Mkt Cap: $0.0B
ENZB
Enzo Biochem, Inc.
$0.70
Mkt Cap: $0.0B
IGXT
IntelGenx Technologies Corp.
$0.17
Mkt Cap: $0.0B
IMMPF
ImmuPharma plc
$0.09
Mkt Cap: $0.0B
LSBCF
LakeShore Biopharma Co., Ltd
$0.84
Mkt Cap: $0.0B
MVRBF
Medivir AB (publ)
$0.82
Mkt Cap: $0.0B
NEVPF
Abliva AB (publ)
$0.03
Mkt Cap: $0.0B
RLFTD
Relief Therapeutics Holding AG
$4.08
Mkt Cap: $0.0B
TREIF
Rocket Doctor Ai Inc.
$0.49
Mkt Cap: $0.0B
Explore stocks similar to DMTTF for comparison